- Home
- MYNZ
MYNZ
Mainz Biomed N.V.
as 10-17-2024 4:00pm EST
| Founded: | 2021 | Country: | Germany |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $3.39 | Next Earning Date: | 11-14-2024 |
| Revenue: | $895,479 | Revenue Growth: | 69.00% |
| Revenue Growth (this year): | 36.69% | Revenue Growth (next year): | 91.67% |
Latest Mainz Biomed N.V. News
MYNZ Breaking Stock News: Dive into MYNZ Ticker-Specific Updates for Smart Investing
TipRanks
7 days ago
Mainz Biomed Secures Additional $1.5M Funding
GlobeNewswire
10 days ago
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
Benzinga
16 days ago
The Covid Era Tech Promises To Reinvent Cancer Treatment
GlobeNewswire
17 days ago
Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
Benzinga
a month ago
Pfizer Advances On Its Cancer Journey
GlobeNewswire
a month ago
Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
MT Newswires
a month ago
Mainz Biomed Expands AI Collaboration With Liquid Biosciences to Include Pancreatic Cancer Test
GlobeNewswire
a month ago
Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
Compare MYNZ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MYNZ Mainz Biomed N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.